Assessment of receptor occupancy-over-time of two dopamine transporter inhibitors by [11C]CIT and target controlled infusion

Upsala Journal of Medical Sciences

Volumn 116, Issue 2, 2011, Pages 100-106

  Eriksson, Olof ^a,c   Långström, Bengt ^a   Josephsson, Ray ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Preclinical PET Platform   (Sweden)

Author keywords

11C CIT; CCIP; DAT inhibitor; SRTM; TCI

Indexed keywords

AMFEBUTAMONE; CARBON; DOPAMINE TRANSPORTER; PIPERAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; VANOXERINE;

ANIMAL; ARTICLE; CORPUS STRIATUM; DRUG ANTAGONISM; FEMALE; HALF LIFE TIME; MACACA MULATTA; METABOLISM; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; BUPROPION; CARBON ISOTOPES; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HALF-LIFE; MACACA MULATTA; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79954545530     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2011.563878     Document Type: Article

References (18)

1. Eriksson O, Wallberg A, Syvänen S, Josephsson R, Långström B, Bergström M. A computerized infusion pump for control of tissue tracer concentration during positron emission tomography in vivo pharmacokinetic/pharmacodynamic measurements. BMC Med Phys. 2008;8:2.
2. Eriksson O, Josephsson R, Långstrom B, Bergström M. Positron emission tomography and target-controlled infusion for precise modulation of brain drug concentration. Nucl Med Biol. 2008;35:299-303. (Pubitemid 351381966)
3. Syvanen S, Blomquist G, Sprycha M, Hoglund AU, Roman M, Eriksson O, et al. Duration and degree of cyclosporine induced P-glycoprotein inhibition in the rat bloodbrain barrier can be studied with PET. Neuroimage. 2000; 32:1134-41.
4. Halldin C, Farde L, Lundkvist C, Ginovart N, Nakashima Y, Karlsson P, et al. 11Cbeta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. Synapse. 1996;22:386-90.
5. Gulley JM, Zahniser NR. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. Eur J Pharmacol. 2003;479:139-52. (Pubitemid 37377883)
6. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: Associa ion between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57:229-38. (Pubitemid 40187366)
7. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvalahti E, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res. 2001; 52:115-20. (Pubitemid 32947054)
8. Uhl GR. Dopamine transporter: basic science and human variaton of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord. 2003;18:71-80.
9. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC. Comparison of bolus and infusion methods for receptor quantitation: Application to 18Fcyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42. (Pubitemid 23016600)
10. Carson RE, Breier A, de Bartolomeis A, Saunders RC, Su TP, Schmall B. Quantification of amphetamine-induced changes in 11Craclopride binding with continuous infusion. J Cereb Blood Flow Metab. 1997;17:437-47. (Pubitemid 27188540)
11. Carson, RE. PET physiological measurements using constant infusion. Nucl Med Bio. 2000;27:657-60.
12. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12:178-207. (Pubitemid 46047787)
13. Rothman RB,Baumann M, Prisinzano TE, Newman AH. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol. 2008;75:2-16. (Pubitemid 350235399)
14. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4: 153-8.
15. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical 11Craclopride studies. J Cereb Blood Flow Metab. 1996;16:42-52.
16. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Långstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54:800-5. (Pubitemid 37205131)
17. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology. 2002;163:102-5. (Pubitemid 34985318)
18. Villemagne VL, Rothman RB, Yokoi F, Rice KC, Matecka D, Dannals RF, et al. Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by 11C WIN35,428 PET scans. Synapse. 1999;32:44-50. (Pubitemid 29124096)